Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Journal
Cancer Medicine
ISSN
2045-7634
Publisher
Wiley
Date Issued
2025
Author(s)
Rizzo, Mimma
Morelli, Franco
Ürün, Yüksel
Buti, Sebastiano
Park, Se Hoon
Bourlon de los Ríos, María Teresa
Grande, Enrique
Massari, Francesco
Landmesser, Johannes
Poprach, Alexandr
Takeshita, Hideki
Roviello, Giandomenico
Myint, Zin W.
Popovic, Lazar
Soares, Andrey
Abahssain, Halima
Giannatempo, Patrizia
Molina‐Cerrillo, Javier
Incorvaia, Lorena
Salah, Samer
Zeppellini, Annalisa
Marques Monteiro, Fernando Sabino
Porta, Camillo
Gupta, Shilpa
Santoni, Matteo
Type
text::journal::journal article
Abstract
Background: Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody–drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting. Methods: The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR). Results: Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2–10.7) in the overall study population, 13.6 months (95%CI 10.0–31.0) in patients receiving EV and 6.8 months (95%CI 6.0–8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5–17.0] vs. 3.0 months [95%CI 2.6–3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort. ©The authors ©Wiley ©Cancer Medicine.
License
Acceso Abierto
How to cite
Rizzo, M., Morelli, F., Ürün, Y., Buti, S., Park, S. H., Bourlon, M. T., Grande, E., Massari, F., Landmesser, J., Poprach, A., Takeshita, H., Roviello, G., Myint, Z. W., Popovic, L., Soares, A., Abahssain, H., Giannatempo, P., Molina‐Cerrillo, J., Incorvaia, L., … Santoni, M. (2025). Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience. Cancer Medicine, 14(4). https://doi.org/10.1002/cam4.70479